


CLAIMS

1. A compound having the following structure:



(I)

or a pharmaceutically acceptable salt, ester, solvate, stereoisomer or prodrug thereof,

wherein:

R_1 and R_2 are the same or different and independently are hydrogen, alkyl, or substituted alkyl;

Ar is phenyl, phenyl substituted by 1 or 2 R_3 , pyridyl or pyridyl substituted by 1 or 2 R_3 ;

R_3 at each occurrence is independently alkyl, substituted alkyl, alkoxy, substituted alkoxy, cyano, halogen, alkylsulfinyl, or alkylsulfonyl;

Het is heterocycle or heterocycle substituted with 1 or 2 R_4 ;

R_4 at each occurrence is independently alkyl, substituted alkyl, alkoxy, substituted alkoxy, halogen, cyano or oxo; and

R_5 and R_6 are the same or different and independently are hydrogen, alkyl or substituted alkyl.

2. A compound according to claim 1, wherein R_1 is alkyl.
3. A compound according to claim 1, wherein R_2 is alkyl or substituted alkyl.
4. A compound according to claim 1, wherein Ar is phenyl substituted by 1

R_3 .

5. A compound according to claim 4, wherein R_3 is alkyl, substituted alkyl, alkoxy, cyano or halogen.
6. A compound according to claim 4, wherein R_3 is halogen.
7. A compound according to claim 1, wherein Het is heterocycle substituted with 1 R_4 .
8. A compound according to claim 7, wherein R_4 is alkyl, substituted alkyl, or alkoxy.
9. A compound according to claim 7, wherein R_4 is oxo.
10. A compound according to claim 3, wherein R_5 at each occurrence is hydrogen.
11. A compound according to claim 10, wherein Ar is phenyl, pyridyl or phenyl substituted by one R_3 , wherein R_3 is halogen.
12. A compound according to claim 11, wherein Ar is phenyl substituted by one R_3 , and wherein R_3 is chloro.
13. A compound according to claim 12, wherein Het is heterocycle.
14. A compound according to claim 13, wherein Het is pyrazole.
15. A compound according to claim 12, wherein Het is heterocycle substituted by one or two R_4 .
16. A compound according to claim 15, wherein Het is dimethylisoxazole.

17. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

18. A method for treating a disorder manifesting hypersecretion of CRF in a mammal comprising administering to the mammal a pharmaceutically effective amount of the pharmaceutical composition of claim 17.

19. A method according to claim 18, wherein the disorder is an affective disorder, an anxiety-related disorder, a feeding disorder, a stress-induced immunosuppressive disorder, an inflammatory disorder or a substance abuse or withdrawal disorder.

20. A method according to claim 18, wherein the disorder is irritable bowel syndrome.

21. A method according to claim 18, wherein the disorder is depression.

22. A method according to claim 18, wherein the disorder is anxiety.

23. A method according to claim 18, wherein the disorder is obsessive-compulsive disorder.

24. A method according to claim 18, wherein the disorder is stroke.